This observational study is comparing two FDA-approved mammography systems, the MAMMOMAT B.brilliant and the MAMMOMAT Revelation, for breast cancer screening. Researchers want to see if the MAMMOMAT B.brilliant, which has a shorter scan time, can provide clearer images of suspicious calcifications (tiny calcium deposits that can sometimes indicate cancer). You might be able to join if you are a woman aged 18 or older, presenting for a diagnostic mammogram at Pennsylvania Hospital due to suspicious calcifications found during a previous screening. The study aims to enroll up to 125 participants. The main goal is to compare the image quality of the two systems, specifically how well they show calcifications, over 18 months.

Study design

This is an observational study comparing two mammography systems, with a planned enrollment of up to 125 women.

What's involved

You would receive a standard diagnostic mammogram on one system and then two additional research images on the other system, which involves 5-25 seconds of compression.

Compensation

Not stated in the trial record.

Follow-up

Data will be collected from enrollment to the end of the study at 18 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.